<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30275857</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">1738-6756</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>21</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of breast cancer</Title>                <ISOAbbreviation>J Breast Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>288-296</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4048/jbc.2018.21.e34</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">Expression of RNA-binding motif protein 3 (RBM3) is induced by hypoxia and hypothermia. Recently, high expression of RBM3 was reported to be associated with a good prognosis in colon cancer, prostate cancer, ovarian cancer, and malignant melanoma. Studies on RBM3 in invasive breast carcinoma (IBC), however, are limited.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">RBM3 expression was examined using a tissue microarray from 361 patients with IBC. Immunohistochemistry was performed for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 to compare the expression of these markers. For scoring of RBM3 expression, NF (nuclear staining fraction)×NI (nuclear staining intensity) was used. The RBM3 expression score was considered indicative of either low (≤4) or high (&gt;4) expression. Western blot analysis was performed on breast cancer cell lines to evaluate RBM3 expression.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Of the total 361 samples, 240 (66.5%) exhibited high RBM3 expression. High RBM3 expression was significantly associated with positivity for ER (<i>p</i>&lt;0.001), PR (<i>p</i>&lt;0.001), T stage (<i>p</i>&lt;0.001), histologic grade (<i>p</i>&lt;0.001), and % Ki-67 staining (<i>p</i>=0.004). Multivariate analysis revealed that high RBM3 expression was closely associated with prolonged disease-free survival (DFS) (<i>p</i>&lt;0.001) and overall survival (OS) (<i>p</i>&lt;0.001). Western blot analysis revealed reduced RBM3 expression in HCC1954 (HER2-enriched) and BT-20 (basal-like) cells with an aggressive phenotype.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">High nuclear RBM3 expression is strongly associated with a prolonged DFS and OS. Furthermore, RBM3 expression is closely associated with good prognostic markers such as ER and PR in IBC. High nuclear RBM3 expression is, therefore, a critical biomarker of favorable clinical outcomes in IBC.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kang</LastName>                    <ForeName>Sun Hee</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Keimyung University School of Medicine, Daegu, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cho</LastName>                    <ForeName>Jihyoung</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Keimyung University School of Medicine, Daegu, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jeong</LastName>                    <ForeName>Hasong</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Keimyung University School of Medicine, Daegu, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kwon</LastName>                    <ForeName>Sun Young</ForeName>                    <Initials>SY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Keimyung University School of Medicine, Daegu, Korea.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute for Cancer Research, Keimyung University School of Medicine, Daegu, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>J Breast Cancer</MedlineTA>            <NlmUniqueID>101314183</NlmUniqueID>            <ISSNLinking>1738-6756</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Anat Pathol. 2007 Nov;14(6):419-30</RefSource>                <PMID Version="1">18049131</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Transl Med. 2011 Jul 21;9:114</RefSource>                <PMID Version="1">21777469</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 1994 Jul 29;265(5172):615-21</RefSource>                <PMID Version="1">8036511</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Mol Genet. 1995 Dec;4(12):2307-11</RefSource>                <PMID Version="1">8634703</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell Proteomics. 2005 Dec;4(12):1920-32</RefSource>                <PMID Version="1">16127175</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2011;6(12):e28446</RefSource>                <PMID Version="1">22145045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2014 Mar;50(4):852-61</RefSource>                <PMID Version="1">24380696</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Res. 2017 Apr;37(4):1779-1785</RefSource>                <PMID Version="1">28373441</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Oncol. 2011 Feb;5(1):5-23</RefSource>                <PMID Version="1">21147047</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2011 Aug;22(8):1736-47</RefSource>                <PMID Version="1">21709140</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2008 Jul 31;27(33):4544-56</RefSource>                <PMID Version="1">18427544</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Treat Rev. 2012 Oct;38(6):698-707</RefSource>                <PMID Version="1">22178455</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Transl Oncol. 2011 Aug;4(4):212-21</RefSource>                <PMID Version="1">21804916</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pediatr Res. 2010 Jan;67(1):35-41</RefSource>                <PMID Version="1">19770690</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biochem. 2006 Apr 15;97(6):1275-82</RefSource>                <PMID Version="1">16552754</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Surg Oncol. 2015 Nov 14;13:317</RefSource>                <PMID Version="1">26577765</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Transl Med. 2010 Aug 20;8:78</RefSource>                <PMID Version="1">20727170</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2015 Mar;65(2):87-108</RefSource>                <PMID Version="1">25651787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Protein Pept Lett. 2016;23(9):828-35</RefSource>                <PMID Version="1">27364162</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Biophys Res Commun. 1997 Jul 30;236(3):804-7</RefSource>                <PMID Version="1">9245737</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pathology. 2009 Jan;41(1):40-7</RefSource>                <PMID Version="1">19089739</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mod Pathol. 2009 Dec;22(12):1564-74</RefSource>                <PMID Version="1">19734850</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biochem. 2005 Jan 1;94(1):5-24</RefSource>                <PMID Version="1">15514923</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Pathol Lab Med. 2010 Jul;134(7):e48-72</RefSource>                <PMID Version="1">20586616</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource>                <PMID Version="1">24101045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res Treat. 2016 Apr;48(2):436-50</RefSource>                <PMID Version="1">26987395</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Sci. 2004 Apr 1;117(Pt 9):1785-94</RefSource>                <PMID Version="1">15075239</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Urol. 2013 Apr 08;13:17</RefSource>                <PMID Version="1">23565664</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diagn Pathol. 2011 Sep 28;6:91</RefSource>                <PMID Version="1">21955582</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Immunohistochemistry</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>            <Keyword MajorTopicYN="N">RNA-binding proteins</Keyword>        </KeywordList>        <CoiStatement>CONFLICT OF INTEREST: The authors declare that they have no competing interests.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>12</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30275857</ArticleId>            <ArticleId IdType="doi">10.4048/jbc.2018.21.e34</ArticleId>            <ArticleId IdType="pmc">PMC6158158</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>